دورية أكاديمية
أعرض في EDS

T- and B-cell responses to multivalent prime-boost DNA and viral vectored vaccine combinations against hepatitis C virus in non-human primates.

التفاصيل البيبلوغرافية
العنوان: T- and B-cell responses to multivalent prime-boost DNA and viral vectored vaccine combinations against hepatitis C virus in non-human primates.
المؤلفون: Rollier CS; Department of Virology, Biomedical Primate Research Centre, Rijswijk, The Netherlands.; Department of Paediatrics, Oxford Vaccine Group, CCVTM Churchill Hospital, University of Oxford, Oxford, UK., Verschoor EJ; Department of Virology, Biomedical Primate Research Centre, Rijswijk, The Netherlands., Verstrepen BE; Department of Virology, Biomedical Primate Research Centre, Rijswijk, The Netherlands., Drexhage JA; Department of Virology, Biomedical Primate Research Centre, Rijswijk, The Netherlands., Paranhos-Baccala G; UMR2714, CNRS-BioMérieux, IFR 128 Biosciences Gerland, Lyon, France., Liljeström P; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden., Sutter G; GSF Institut für Molekular Virology, Munich, Germany., Arribillaga L; Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), University of Navarra, IdiSNA, Pamplona, Spain., Lasarte JJ; Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), University of Navarra, IdiSNA, Pamplona, Spain., Bartosch B; CIRI-International Center for Infectiology Research, Université de Lyon; Inserm, U1111; Ecole Normale Supérieure de Lyon; Université Lyon 1, Centre International de Recherche en Infectiologie; CNRS, UMR5308; LabEx Ecofect, Université de Lyon, Lyon, France., Cosset FL; CIRI-International Center for Infectiology Research, Université de Lyon; Inserm, U1111; Ecole Normale Supérieure de Lyon; Université Lyon 1, Centre International de Recherche en Infectiologie; CNRS, UMR5308; LabEx Ecofect, Université de Lyon, Lyon, France., Inchauspe G; UMR2714, CNRS-BioMérieux, IFR 128 Biosciences Gerland, Lyon, France., Heeney JL; Department of Virology, Biomedical Primate Research Centre, Rijswijk, The Netherlands.
المصدر: Gene therapy [Gene Ther] 2016 Oct; Vol. 23 (10), pp. 753-759. Date of Electronic Publication: 2016 Jul 14.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 9421525 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5462 (Electronic) Linking ISSN: 09697128 NLM ISO Abbreviation: Gene Ther Subsets: MEDLINE
أسماء مطبوعة: Publication: London : Nature Publishing Group
Original Publication: Houndmills, Basingstoke, Hampshire, UK : Macmillan Press Ltd., c1994-
مواضيع طبية MeSH: B-Lymphocytes/*immunology , Epitopes/*genetics , Hepacivirus/*immunology , T-Lymphocytes/*immunology , Viral Hepatitis Vaccines/*immunology, Adenoviridae/genetics ; Animals ; Cell Line ; Cricetinae ; Epitopes/immunology ; Genetic Vectors/genetics ; Immunogenicity, Vaccine ; Interferon-gamma/blood ; Interleukin-4/blood ; Macaca mulatta ; Male ; Vaccinia virus/genetics ; Viral Hepatitis Vaccines/genetics
مستخلص: Immune responses against multiple epitopes are required for the prevention of hepatitis C virus (HCV) infection, and the progression to phase I trials of candidates may be guided by comparative immunogenicity studies in non-human primates. Four vectors, DNA, SFV, human serotype 5 adenovirus (HuAd5) and Modified Vaccinia Ankara (MVA) poxvirus, all expressing hepatitis C virus Core, E1, E2 and NS3, were combined in three prime-boost regimen, and their ability to elicit immune responses against HCV antigens in rhesus macaques was explored and compared. All combinations induced specific T-cell immune responses, including high IFN-γ production. The group immunized with the SFV+MVA regimen elicited higher E2-specific responses as compared with the two other modalities, while animals receiving HuAd5 injections elicited lower IL-4 responses as compared with those receiving MVA. The IFN-γ responses to NS3 were remarkably similar between groups. Only the adenovirus induced envelope-specific antibody responses, but these failed to show neutralizing activity. Therefore, the two novel regimens failed to induce superior responses as compared with already existing HCV vaccine candidates. Differences were found in response to envelope proteins, but the relevance of these remain uncertain given the surprisingly poor correlation with immunogenicity data in chimpanzees, underlining the difficulty to predict efficacy from immunology studies.
References: J Infect Dis. 2005 Sep 1;192(5):920-9. (PMID: 16088843)
Curr Opin Immunol. 2011 Jun;23(3):377-82. (PMID: 21514130)
J Virol. 2016 Jan 06;90(6):3112-22. (PMID: 26739044)
Gastroenterology. 2012 May;142(6):1279-1287.e3. (PMID: 22537434)
Curr Opin Immunol. 2015 Aug;35:137-43. (PMID: 26241306)
Hepatology. 2015 Dec;62(6):1670-82. (PMID: 26251214)
Mol Ther. 2012 Mar;20(3):669-78. (PMID: 21952169)
Proc Natl Acad Sci U S A. 1990 Dec;87(24):9524-8. (PMID: 2175903)
Hepatology. 2000 Sep;32(3):618-25. (PMID: 10960458)
Mol Ther. 2013 Sep;21(9):1787-95. (PMID: 23774793)
Vaccine. 2013 Sep 6;31(39):4223-30. (PMID: 23746455)
Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1294-8. (PMID: 7509068)
PLoS One. 2011;6(9):e24517. (PMID: 21931737)
J Virol. 2004 Jan;78(1):187-96. (PMID: 14671100)
Sci Transl Med. 2014 Nov 5;6(261):261ra153. (PMID: 25378645)
J Virol. 2004 Apr;78(7):3333-42. (PMID: 15016855)
J Immunol. 2003 Aug 1;171(3):1602-9. (PMID: 12874255)
Expert Rev Vaccines. 2013 Apr;12(4):365-78. (PMID: 23560918)
J Virol. 2004 Apr;78(8):3965-76. (PMID: 15047812)
J Immunol. 2011 Aug 1;187(3):1347-57. (PMID: 21715686)
Hepatology. 2016 Apr;63(4):1120-34. (PMID: 26710081)
Expert Rev Vaccines. 2009 Mar;8(3):333-45. (PMID: 19249975)
Arch Virol Suppl. 1992;4:234-7. (PMID: 1450693)
J Virol. 2005 Mar;79(5):2678-88. (PMID: 15708987)
Vaccine. 2016 Feb 17;34(8):1115-25. (PMID: 26700891)
Vaccine. 2002 Dec 13;21(3-4):202-10. (PMID: 12450695)
Gastroenterology. 1999 Oct;117(4):933-41. (PMID: 10500077)
J Virol. 2015 Aug;89(16):8525-39. (PMID: 26041302)
J Virol. 1999 Feb;73(2):1092-8. (PMID: 9882310)
World J Hepatol. 2015 Jan 27;7(1):53-69. (PMID: 25624997)
J Virol. 2002 Dec;76(24):12735-46. (PMID: 12438599)
Nature. 2013 Sep 12;501(7466):237-41. (PMID: 23903655)
BMC Med. 2015 Aug 20;13:198. (PMID: 26289050)
Hepatology. 2007 Mar;45(3):602-13. (PMID: 17326154)
Gastroenterology. 2010 Sep;139(3):965-74. (PMID: 20621699)
PLoS One. 2012;7(8):e41936. (PMID: 22870265)
J Exp Med. 2003 Mar 3;197(5):633-42. (PMID: 12615904)
Hum Vaccin Immunother. 2014;10(8):2357-65. (PMID: 25424943)
Expert Opin Biol Ther. 2013 Aug;13(8):1109-24. (PMID: 23651228)
Microb Pathog. 2013 May;58:66-72. (PMID: 23499591)
J Virol. 2015 Sep;89(18):9154-66. (PMID: 26085155)
PLoS One. 2009 Nov 12;4(11):e7790. (PMID: 19915662)
المشرفين على المادة: 0 (Epitopes)
0 (Viral Hepatitis Vaccines)
207137-56-2 (Interleukin-4)
82115-62-6 (Interferon-gamma)
تواريخ الأحداث: Date Created: 20160715 Date Completed: 20170724 Latest Revision: 20200325
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC7091906
DOI: 10.1038/gt.2016.55
PMID: 27416077
قاعدة البيانات: MEDLINE
الوصف
تدمد:1476-5462
DOI:10.1038/gt.2016.55